CMECME Group
Is the price fair?
At the top of its own P/E range. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Expensive vs its own history: P/E 25.9 vs a 21.6 median over 41 quarters (+20% vs median).
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What CME's price assumes
CME Group trades at 25.9× earnings against 26.2× for the median Financial Data & Stock Exchanges name, cheaper than its own group.
Trailing P/E · Financial Data & Stock Exchanges median 26.2 · cheaper than the typical name in its group
- Price / sales
- 11.8
Price / sales · as of 2026-Q2
- Price / book
- 3.01
Price / book · as of 2026-Q2
- EV / sales
- 11.9
EV / sales
Details›
- Price / bookas of 2026-Q2
- 3.01
- EV / EBITas of 2026-Q2
- 18.4
- EV / salesas of 2026-Q2
- 11.9
- Financial Services median P/E599 names
- 12.5
- Financial Data & Stock Exchanges median P/E12 names
- 26.2
- Market capitalisation359.6 million shares, counted Jul 8, 2026
- $109.9B
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $226.90 |
| Its own P/E history, median | $255.01 |
| Its own P/E history, upper quartile | $295.58 |
| 52-week range | $218.55 – $317.19 |
| Today | $305.71 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.